JP2018522843A5 - - Google Patents

Download PDF

Info

Publication number
JP2018522843A5
JP2018522843A5 JP2017564450A JP2017564450A JP2018522843A5 JP 2018522843 A5 JP2018522843 A5 JP 2018522843A5 JP 2017564450 A JP2017564450 A JP 2017564450A JP 2017564450 A JP2017564450 A JP 2017564450A JP 2018522843 A5 JP2018522843 A5 JP 2018522843A5
Authority
JP
Japan
Prior art keywords
carboxy
ethoxy
amino
butanoyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017564450A
Other languages
English (en)
Japanese (ja)
Other versions
JP6731958B2 (ja
JP2018522843A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/063429 external-priority patent/WO2016198682A1/en
Publication of JP2018522843A publication Critical patent/JP2018522843A/ja
Publication of JP2018522843A5 publication Critical patent/JP2018522843A5/ja
Application granted granted Critical
Publication of JP6731958B2 publication Critical patent/JP6731958B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017564450A 2015-06-12 2016-06-13 選択的pyy化合物及びその使用 Active JP6731958B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15171785.7 2015-06-12
EP15171785 2015-06-12
PCT/EP2016/063429 WO2016198682A1 (en) 2015-06-12 2016-06-13 Selective pyy compounds and uses thereof

Publications (3)

Publication Number Publication Date
JP2018522843A JP2018522843A (ja) 2018-08-16
JP2018522843A5 true JP2018522843A5 (enExample) 2019-07-11
JP6731958B2 JP6731958B2 (ja) 2020-07-29

Family

ID=53404384

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017564450A Active JP6731958B2 (ja) 2015-06-12 2016-06-13 選択的pyy化合物及びその使用

Country Status (19)

Country Link
US (1) US10005824B2 (enExample)
EP (1) EP3307768B1 (enExample)
JP (1) JP6731958B2 (enExample)
KR (1) KR102476550B1 (enExample)
CN (1) CN107849110B (enExample)
AR (1) AR104984A1 (enExample)
AU (1) AU2016275735B2 (enExample)
BR (1) BR112017025108A2 (enExample)
CA (1) CA2988500A1 (enExample)
ES (1) ES3019234T3 (enExample)
IL (1) IL255781B (enExample)
MA (1) MA43205A (enExample)
MX (1) MX392572B (enExample)
MY (1) MY187047A (enExample)
RU (1) RU2726777C2 (enExample)
SA (1) SA517390445B1 (enExample)
TW (1) TWI694082B (enExample)
WO (1) WO2016198682A1 (enExample)
ZA (1) ZA201707782B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56998B1 (sr) 2010-12-16 2018-05-31 Novo Nordisk As Čvrste kompozicije koje sadrže agonist glp-1 i so n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline
CN104203266B (zh) 2012-03-22 2017-12-26 诺和诺德股份有限公司 Glp‑1肽组合物及其制备
BR112015026325A2 (pt) 2013-05-02 2017-07-25 Novo Nordisk As dosagem oral de compostos glp-1
WO2015071356A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Hpyy(1 -36) having a beta-homoarginine substitution at position 35
CA2929672A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof
JP2019518065A (ja) 2016-06-14 2019-06-27 ピュアサークル ユーエスエー インコーポレイテッド ステビオール配糖体組成物、製造方法および使用
WO2019149880A1 (en) 2018-02-02 2019-08-08 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
TWI865836B (zh) 2018-11-01 2024-12-11 美商美國禮來大藥廠 蛋白質酪胺酸-酪胺酸類似物及其使用方法
AU2019383976B2 (en) 2018-11-19 2025-07-03 Bt Bidco, Inc. Methods and devices for treating a disease with biotherapeutics
JP2022543826A (ja) * 2019-08-07 2022-10-14 ノヴォ ノルディスク アー/エス Pyy化合物とn-(8-(2-ヒドロキシベンゾイル)アミノ)カプリル酸の塩とを含む固形組成物
MX2022005661A (es) * 2019-11-11 2022-09-07 Boehringer Ingelheim Int Agonistas del receptor npy2.
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
PE20231566A1 (es) 2020-08-07 2023-10-04 Boehringer Ingelheim Int Agonistas del receptor npy2 solubles
CA3197916A1 (en) * 2020-11-09 2022-05-12 Magnus Bernt Fredrik Gustafsson Compounds and their use in treatment of tachykinin receptor mediated disorders
EP4281464A4 (en) 2021-01-20 2025-01-01 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
AU2022347024A1 (en) 2021-09-15 2024-05-02 Viking Therapeutics, Inc. Compositions and methods for the treatment of metabolic and liver disorders
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023084118A1 (en) 2021-11-15 2023-05-19 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299052A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
WO2024038067A1 (en) 2022-08-18 2024-02-22 Boehringer Ingelheim International Gmbh Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists
CN115960258B (zh) * 2022-09-30 2024-01-12 广西医科大学附属肿瘤医院 一类GLP-1/glucagon/Y2受体三重激动剂及其应用
WO2025128626A1 (en) * 2023-12-12 2025-06-19 Carmot Therapeutics, Inc. Hybrid peptide compounds having a modified lysine residue

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ265452A (en) 1993-03-29 1997-09-22 Univ Cincinnati Analogues of peptide yy, dimers and pharmaceutical compositions
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
WO1998020885A1 (en) 1996-11-13 1998-05-22 University Of Cincinnati Analogs of peptide yy and uses thereof
EP0908515A3 (en) 1997-09-16 2000-04-26 Smithkline Beecham Plc Pancreatic polypeptide
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
CN1311773A (zh) 1998-06-08 2001-09-05 先灵公司 神经肽y5受体拮抗剂
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
EP2123293A3 (en) 2000-12-14 2010-09-08 Amylin Pharmaceuticals, Inc. Peptide YY and petide YY agonists for treatment of metabolic disorders
US6589938B2 (en) 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
NZ532427A (en) 2001-09-24 2008-07-31 Imp Innovations Ltd Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
EP2277527A3 (en) 2003-01-17 2011-08-31 Ipsen Pharma Peptide YY analogs
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
WO2005027978A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
CN100444898C (zh) 2003-09-19 2008-12-24 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
EP1667724A2 (en) 2003-09-19 2006-06-14 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
CN1893980A (zh) 2003-12-18 2007-01-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
RU2378285C2 (ru) 2004-02-11 2010-01-10 Амилин Фармасьютикалз, Инк. Гибридные полипептиды с селектируемыми свойствами
EP2335716A3 (en) 2004-02-11 2011-10-19 Amylin Pharmaceuticals Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
CN1933848A (zh) 2004-03-17 2007-03-21 7Tm制药联合股份有限公司 用于治疗性干预的y2选择性受体激动剂
EP2272524A3 (en) 2004-03-17 2011-02-02 7TM Pharma A/S Y2 selective receptor agonists for therapeutic interventions
CA2560166A1 (en) * 2004-03-17 2005-09-29 7Tm Pharma A/S Y2/y4 selective receptor agonists for therapeutic interventions
MXPA06010345A (es) 2004-03-17 2007-06-19 7Tm Pharma As Agonistas de receptor selectivo de y4 para intervenciones terapeuticas.
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
WO2006005667A2 (en) 2004-07-08 2006-01-19 Novo Nordisk A/S Polypeptide protracting tags comprising a tetrazole moiety
US7994119B2 (en) 2004-07-19 2011-08-09 University Of Cincinnati Compounds for control of appetite
CN101035512B (zh) * 2004-08-12 2012-01-18 昌达生物科技公司 用于生物活性化合物可控制释放递送的药物组合物
WO2006049681A2 (en) 2004-08-30 2006-05-11 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
US7410949B2 (en) 2005-01-18 2008-08-12 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
GB0504857D0 (en) 2005-03-09 2005-04-13 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
KR20080033392A (ko) 2005-07-11 2008-04-16 나스텍 파마수티컬 컴퍼니 인코포레이티드 펩타이드 yy의 향상된 점막 전달을 위한 제형들
US20090203581A1 (en) 2005-07-18 2009-08-13 Novo Nordisk A/S Novel Peptides for Use in the Treatment of Obesity
AU2006279680B2 (en) * 2005-08-11 2012-12-06 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
WO2007038942A1 (en) 2005-09-21 2007-04-12 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
CA2623094A1 (en) 2005-09-21 2007-04-12 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
EP1962959B1 (en) 2005-12-07 2012-03-14 F. Hoffmann-La Roche AG Neuropeptide-2 receptor-agonists
US20100029903A1 (en) 2005-12-14 2010-02-04 Novo Nordisk A/S Polypeptide Protracting Tags
US20070197445A1 (en) 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
WO2007109354A2 (en) 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
GB0613196D0 (en) 2006-07-03 2006-08-09 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
CA2657911C (en) * 2006-07-11 2012-02-21 Quest Pharmaceutical Services, Llc Pharmaceutical compositions for sustained release delivery of peptides
GB0621973D0 (en) 2006-11-03 2006-12-13 Philogen Spa Binding molecules and uses thereof
US20090099074A1 (en) 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
EP2101822A2 (en) 2007-01-18 2009-09-23 Novo Nordisk A/S Use of peptides in combination with surgical intervention for the treatment of obesity
WO2008087186A2 (en) 2007-01-18 2008-07-24 Novo Nordisk A/S Peptides for use in the treatment of obesity
GB0708226D0 (en) 2007-04-27 2007-06-06 7Tm Pharma As Y-receptor agonists
US20100279930A1 (en) 2007-07-09 2010-11-04 Stephen Robert Bloom Human pancreatic polypeptide (hpp) analogues and their effects on feeding behaviour
CN101842109B (zh) 2007-09-05 2014-01-29 诺沃-诺迪斯克有限公司 用a-b-c-d-衍生的肽和它们的治疗用途
WO2009043477A2 (en) * 2007-09-11 2009-04-09 Mondobiotech Laboratories Ag Use of glpl (7-36) alone or in combination with leptin 22-56 as a therapeutic agent
US8598314B2 (en) 2007-09-27 2013-12-03 Amylin Pharmaceuticals, Llc Peptide-peptidase-inhibitor conjugates and methods of making and using same
KR20110017874A (ko) * 2008-05-16 2011-02-22 노보 노르디스크 에이/에스 오래 작용하는 y2 및/또는 y4 수용체 작용제
US8299023B2 (en) 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
GB0817067D0 (en) 2008-09-18 2008-10-22 7Tm Pharma As Intestinal treatment
KR20110097807A (ko) 2008-11-05 2011-08-31 에프. 호프만-라 로슈 아게 뉴로펩티드-2-수용체(y-2r) 작용제 및 이의 용도
EP2398492A4 (en) 2009-02-20 2013-07-17 Ipsen Pharma Sas CYTOTOXIC CONJUGATES HAVING NEUROPEPTIDE Y RECEPTOR BINDING COMPOUND
CN102573888A (zh) * 2009-09-18 2012-07-11 诺和诺德公司 长效y2 受体激动剂
EP2488195A2 (en) 2009-10-13 2012-08-22 F. Hoffmann-La Roche AG Neuropeptide-2 receptor (y-2r) agonists
US20130096055A1 (en) 2009-11-13 2013-04-18 Novo Nordisk A/S Long-acting y2 receptor agonists
WO2011131646A1 (en) 2010-04-20 2011-10-27 Novo Nordisk A/S Long-acting gastrin derivatives
GB201101459D0 (en) 2011-01-27 2011-03-16 Imp Innovations Ltd Novel compounds and thier effects on fedding behaviour
EP2855517A1 (en) 2012-05-29 2015-04-08 Novo Nordisk A/S Pancreatic polypeptide compounds and use
CN105263957A (zh) 2013-05-02 2016-01-20 葛兰素史克知识产权开发有限公司 治疗肽
WO2015071356A1 (en) * 2013-11-15 2015-05-21 Novo Nordisk A/S Hpyy(1 -36) having a beta-homoarginine substitution at position 35
CA2929672A1 (en) * 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof

Similar Documents

Publication Publication Date Title
JP2018522843A5 (enExample)
JP2017505284A5 (enExample)
RU2017145348A (ru) Селективные соединения пептида yy и их применения
JP6379300B2 (ja) GLP及び免疫グロブリンハイブリッドFc融合ポリペプチド及びその用途
JP2017500289A5 (enExample)
Cho et al. K-cells and glucose-dependent insulinotropic polypeptide in health and disease
RU2523552C2 (ru) Лекарственное средство, включающее совместное применение или комбинацию ингибитора dpp-iv и другого лекарственного средства для лечения диабета
RU2015147876A (ru) Пероральная дозированная форма соединений глюкагоноподобного пептида-1
JP2017537612A5 (enExample)
JP2015513544A5 (enExample)
JP2014500880A5 (enExample)
JP2023071869A (ja) グルカゴンおよびglp-1受容体の長時間作用型コアゴニスト
JP2015503539A5 (enExample)
NO20076346L (no) Fremgangsmater for forebygging og behandling av metabolske forstyrrelser og nye pyrazol-o-glykosidderivater
JP2017519024A5 (enExample)
JP2010538049A5 (enExample)
JP2011503152A5 (enExample)
JP2025144567A (ja) グルカゴン、及びglp-1受容体及びgip受容体二重アゴニストを含む組成物及びその治療学的使用
JP2018505146A5 (enExample)
JP2015517458A5 (enExample)
JP2022542830A (ja) Eyp001を使用した改善された処置
JP2017509628A5 (enExample)
TW202140074A (zh) Fgf-21結合物調配物
JP2013511287A5 (enExample)
CN113456820B (zh) 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途